Free Trial
Tessa Romero

Tessa Romero Analyst Performance

Senior Analyst - Biotechnology Equity Research at JPMorgan Chase & Co.

Tessa Romero is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 7 publicly traded companies. Over the past year, Tessa Romero has issued 10 stock ratings, including buy, hold, and sell recommendations. While full access to Tessa Romero's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tessa Romero's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 0 Years
Buy Recommendations
70.00% 7 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.0%7 ratings
Hold20.0%2 ratings
Sell10.0%1 ratings

Out of 10 total stock ratings issued by Tessa Romero at JPMorgan Chase & Co., the majority (70.0%) have been Buy recommendations, followed by 20.0% Hold and 10.0% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Tessa Romero, an analyst at JPMorgan Chase & Co., currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Tessa Romero of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
71.4%
MED - DRUGS
2 companies
28.6%

Tessa Romero's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
9/16/2025Downgrade$1.52Underweight
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
8/19/2025Lower Price Target$13.83$30.00Overweight
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
7/24/2025Boost Price Target$23.16$34.00Overweight
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
7/15/2025Lower Price Target$8.35$9.00Neutral
Biohaven Ltd. stock logo
BHVN
Biohaven
6/18/2025Lower Price Target$14.58$55.00Overweight
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
6/9/2025Lower Price Target$32.65$53.00Overweight
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
6/6/2025Boost Price Target$22.05$30.00Overweight
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5/30/2025Lower Price Target$2.76$10.00Overweight
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/21/2025Lower Price Target$12.18$17.00Neutral
Biohaven Ltd. stock logo
BHVN
Biohaven
3/5/2025Lower Price Target$30.90$68.00Overweight